About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, March 30th, 2017

The QualityStocks
Daily Stock List


Exactus, Inc. (EXDI)

We are reporting on Exactus, Inc. (EXDI) today, here at the QualityStocks Daily Newsletter.

Exactus, Inc. is a life science company with its corporate headquarters in Richmond, Virginia. The Company is developing and commercializing ultra-fast, handheld, point-of-care (POC) diagnostic tools powering informed patient management.  Exactus is developing for commercialization POC diagnostics for measuring proteolytic enzymes in the blood based on a novel, proprietary detection platform. Exactus lists on the OTC Markets Group’s OTCQB.

The Company’s devices can eliminate the requirement to send patient samples to a laboratory and wait for test results. Exactus is developing the first handheld test to measure fibrinolytic activity and the first at-home test to detect the onset of metastasis. It is designing products with the potential to deliver quick, actionable information to physicians to provide improved treatment decisions for patients, better health outcomes, as well as long term reduction in healthcare costs.

The Company’s hand-held POC diagnostic tools will analyze a single drop of blood employing Exactus’ proprietary biosensor technology. The Company’s FibriLyzer™ is undergoing design to be a user-friendly, handheld detection unit, which utilizes proprietary technology to employ a disposable assay test "biosensor" strip. The device provides (using only a drop of blood) a readout of a patient's fibrinolysis status in as little as 30 seconds.

In addition, the design of the Company’s MatriLyzer™ is to be a mobile screening device that monitors collagenase levels over time. Using a smartphone application (app), results of the test would automatically be telemetered to a patient's electronic medical record. This would alert the attending oncologist of a change in a patient's status, which may require a more thorough examination.

In December 2016, Exactus announced the appointment of James R. Erickson, Ph.D. as Chief Business Officer. Dr. Erickson began his career as a post-doc at Onyx Pharmaceuticals. He has since worked mainly in business development roles for diagnostic and biopharmaceutical companies, including AGY Therapeutics, Entelos, and Titan Pharmaceuticals.

Exactus, Inc. (EXDI), closed Thursday's trading session at $0.45, up 12.50%, on 47,500 volume with 4 trades. The average volume for the last 60 days is 2,673 and the stock's 52-week low/high is $0.302/$2.50.

MYnd Analytics, Inc. (MYAN)

Today we are reporting on MYnd Analytics, Inc. (MYAN), here at the QualityStocks Daily Newsletter.

MYnd Analytics, Inc. is a predictive medicine company listed on the OTCQB.  Mynd brings objective physical findings to psychiatric treatment to decrease trial and error treatment in mental health. The Company provides an innovative set of reference data and analytic tools for clinicians and researchers in psychiatry. MYnd Analytics has its Psychiatric EEG Evaluation Registry, or PEER Online®. The aim of PEER Online is to provide objective, personalized data to assist physicians in the selection of appropriate medications.

PEER Online (a cloud-based platform), is a registry and reporting platform. It allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained by way of a standard electroencephalogram (EEG).  Based on the Company’s original physician-developed database, there are currently greater than 38,000 outcomes for more than 10,000 unique patients in the PEER registry.

PEER was developed by physicians to provide objective information about medication response for similar patients.  PEER combines a "crowdsourced" secure physician outcome registry with electroencephalogram (EEG), an accepted, well-normed test of brain function. EEG is a totally painless, non-invasive test. It records one’s brain’s electrical activity.

In essence, physicians built this platform, they contribute new outcomes as they see patients, and they will never be finished building the registry. Physicians who use PEER lessen trial and error prescribing.

Mynd Analytics has its MYnd Analytics Center. This Center provides a convenient, relaxing, and welcoming environment for one to receive their EEG and PEER Report™. The EEG is performed on-site at the MYnd Analytics Center. It typically takes less than one hour. The EEG and PEER Report are available by appointment only.

Last week, MYnd Analytics announced receipt of a one-million-dollar strategic investment by the European-based RSJ Gradus fund. This includes a right of first refusal to expand into Europe before the end of 2018.

Mr. George Carpenter, MYnd Analytics’ Chief Executive Officer, said, “MYnd has begun its expansion into Canada in collaboration with the Canadian Military and looks forward to further global expansion in areas where there is an opportunity to improve the treatment of mental health illnesses.”

MYnd Analytics, Inc. (MYAN), closed Thursday's trading session at $5.90, down 1.67%, on 10,950 volume with 37 trades. The average volume for the last 60 days is 1,002 and the stock's 52-week low/high is $2.80/$10.00.

Vitality Biopharma, Inc. (VBIO)

SmallCap Network, Stock Beast, and Promotion Stock Secrets reported earlier on Vitality Biopharma, Inc. (VBIO), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

Vitality Biopharma, Inc.’s commitment is to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. Since 2012, Vitality has developed a unique capability for the production of molecules through glycosylation, a form of enzymatic biosynthesis, which was originally developed to improve the taste of stevia, a high-potency sweetener. The platform is well suited for the discovery of new pharmaceutical products. Vitality Biopharma has its corporate headquarters in Los Angeles, California.

Vitality Biopharma, late in 2015, successfully modified cannabidiol (CBD), which is not psychoactive, and in continuing work has created a novel class of pharmaceuticals known as cannabosides. Cannabosides, upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits. This is while lessening or avoiding the systemic delivery of THC into the bloodstream.

The Company can biosynthesize cannabinoid glycosides (cannabosides) through enzyme biosynthesis. Vitality Biopharma is one of only a very few groups around the world who know how to produce and work with the enzymes that perform glycosylation. It has been focused on it because the same enzymes are used to modify the taste of the aforementioned stevia (steviol glycosides).

In early March, Vitality Biopharma announced that it created a library of proprietary glycosides of THC (delta-9-tetrahydrocannabinol), the primary psychoactive chemical found in cannabis or marijuana that enable targeted delivery, which lessens or eliminates psychoactivity when used in oral drug formulations. The compounds are undergoing development as pharmaceuticals that enable site-specific targeting of the THC in different tissues of the body, where it can exert therapeutic effects for treatment of pain and inflammation.

Vitality Biopharma obtained DEA approval in December 2016 for its research and development facilities in California. It has now completed preclinical pharmacokinetics studies with its proprietary THC glycosides to analyze their bioavailability. Vitality has confirmed that large concentrations can be delivered orally without significant transit of THC to the brain, enabling their formulation within pharmaceuticals where drug psychoactivity will be decreased or eliminated.

Today, Vitality Biopharma announced that it has positive results indicating a new use for its proprietary prodrug cannabinoid delivery platform. Numerous colon cancer cell kinds were screened, each with unique combinations of genetic mutations that drive cancerous growth, and including a cell line known to express drug-resistance genes such as PD-L1.

Vitality Biopharma found that cannabidiol (CBD) universally inhibited cell growth at concentrations alike to established chemotherapeutics. In addition, the Company found that its cannabidiol prodrug was not toxic to the human cells at the concentrations tested, demonstrating the relative safety of its prodrug delivery system.

Vitality Biopharma, Inc. (VBIO), closed Thursday's trading session at $1.85, up 20.92%, on 819,551 volume with 1,152 trades. The average volume for the last 60 days is 254,970 and the stock's 52-week low/high is $0.463/$4.24.

Boston Therapeutics, Inc. (BTHE)

Wall Street Mover, RedChip, TaglichBrothers, Stock News Now, TopPennyStockMovers, SmallCapVoice, PennyStocks24, MissionIR, Tiny Gems, FeedBlitz, and Information Solutions Group reported earlier on Boston Therapeutics, Inc. (BTHE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Boston Therapeutics, Inc. is a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases. Its product pipeline focuses on developing and commercializing therapeutic molecules, which address diabetes and inflammatory diseases. The Company also developed and markets SUGARDOWN®. This is a non-systemic, complex carbohydrate-based dietary food supplement. The design of SUGARDOWN® is to support healthy blood glucose. Boston Therapeutics is headquartered in Lawrence, Massachusetts, and lists on the OTC Bulletin Board.

The Company’s product pipeline includes BTI-320. This is a non-systemic, non-toxic, chewable complex carbohydrate-based compound. The design of it is to decrease post-meal glucose elevation. BTI-320 is a proprietary polysaccharide. BTI-320 works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down complex carbohydrates into simple sugars, decreasing the availability of glucose for absorption into the bloodstream.

Boston Therapeutics entered a clinical trial agreement with Joslin Diabetes Center to be the lead clinic in a Phase II study of BTI-320. Furthermore, the Company’s product pipeline includes IPOXYN™. This is an injectable anti-necrosis drug. The design of it initially is to treat lower limb ischemia associated with diabetes.

Boston Therapeutics’ product pipeline also includes OXYFEX™. This product can serve as the only available oxygen delivery mechanism for animals suffering ischemia or traumatic and surgical blood loss events. OXYFEX™ is the Company’s veterinary facsimile to IPOXYN™.

Boston Therapeutics announced in 2015 that its affiliate, Advance Pharmaceutical, initiated the SUGARDOWN® clinical trial in Hong Kong. Advance Pharmaceutical is evaluating the effect of SUGARDOWN® on Post-Prandial Hyperglycemia in Chinese subjects with Pre-Diabetes. The lead clinical site is the Department of Medicine, The Chinese University of Hong Kong (CUHK), Prince of Wales Hospital.

Advance Pharmaceutical is conducting this clinical trial at CUHK to evaluate BTI-320 in subjects who are pre-diabetic. The interim clinical analysis in the proof of concept trial demonstrate up to 77 percent reduction in Glucose and up to 27 percent in Fructose.

Essentially, Boston Therapeutics is concentrating on developing, commercializing, and partnering and also exploring international merger opportunities to take advantage of therapeutic molecules and therapeutic protein combinations, which address prediabetes, diabetes, and inflammatory diseases. For this year, Boston Therapeutics will initiate the accepted Food and Drug Administration (FDA) IND clinical trial with the Joslin Diabetes Centre and will increase new sites for a multicenter expansion, which its Asian collaborator supports.

Moreover, collaboration opportunities with a number of Contract Research Organizations (CRO’s) in China is continuing and presently progressing to exploit the best of the Company’s collaboration opportunity for cost sharing and resource planning for all registrations for Asia and the US/EU.

Boston Therapeutics, Inc. (BTHE), closed Thursday's trading session at $0.071, up 42.00%, on 7,300 volume with 2 trades. The average volume for the last 60 days is 14,628 and the stock's 52-week low/high is $0.033/$0.17.

Enertopia Corp. (ENRT)

Equities, MassiveStockProfits, Wall Street Equities Research, Stockgoodies, GrowthPennyStocks, Penny Stock General, Shiznit Stocks, Cannabis Financial Network News, PennyStocks24, Fast Money Alerts, Stock Shock and Awe, Penny Champions, Penny Dreamers, OTPicks, and TheMicrocapNews reported on Enertopia Corp. (ENRT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Enertopia Corp. is exploring a portfolio of three prospective lithium projects in the State of Nevada. It is also reviewing other mineral projects. Additionally, at the same time, the Company is working with water purification technology partner Genesis Water Technologies (GWT) utilizing patent pending technology believed able to recover Lithium from brine solutions. Enertopia is based in Vancouver, British Columbia.

Enertopia announced, in April of 2016, the creation of a Lithium business division for the exploration of Lithium. In May 2016, it closed the definitive agreement for the Lithium exploration project in Nevada. In June 2016, Enertopia announced its Surface Exploration Program in Nevada. In Nevada, Enertopia has 2,560 acres of placer mining claims staked in Edwards, Smith, as well as Big Smoky valleys.

The Central Nevada Lithium Brine Projects are proximal to an existing lithium mine. There is all weather access on paved roads and its an ideal evaporation climate.

Regarding water purification technology partner Genesis Water Technologies (GWT), this company is a manufacturer of advanced, innovative and sustainable treatment solutions for applications in process water, drinking water, water reuse and waste water for the energy, agriculture processing, industrial, municipal infrastructure, and building/hotel sectors.

Earlier this month, Enertopia announced it received results from Genesis Water Technologies (GWT) lithium recovery bench tests of four synthetic brine samples employing GWTs patent pending process. The first goal of the four separate bench tests was to confirm the estimated 90 percent recovery rate of Lithium (Li) from various brines sources as per the June 2016 theoretical feasibility study. The recovery rates for Lithium in the four synthetic brines analyzed were from 77.87 percent to 85.62 percent over a testing period of 24 hours.

Yesterday, Enertopia announced that it was notified by the third-party laboratory that the Lithium Carbonate purity testing is taking place on the four Lithium carbonate samples recently produced from the Genesis Water Technologies (GWT) bench tests. The third-party laboratory is using Ion Chromatography to ascertain the precise purity in the submitted four Lithium carbonate samples. Enertopia has expedited the time for testing the samples. The Company believes it will have the purity results within two weeks.

Enertopia Corp. (ENRT), closed Thursday's trading session at $0.0925, up 31.21%, on 365,008 volume with 63 trades. The average volume for the last 60 days is 382,511 and the stock's 52-week low/high is $0.0086/$0.1009.


The QualityStocks
Company Corner


Bollente Companies, Inc. (BOLC)

The QualityStocks Daily Newsletter would like to spotlight Bollente Companies, Inc. (BOLC). Today, Bollente Companies, Inc. closed trading at $0.69, off by 1.43%, on 3,180 volume with 6 trades. The stock’s average daily volume over the past 60 days is 8,893 and its 52-week low/high is $0.20/$1.08.

Founded in 1999, Bollente Companies, Inc. (BOLC) is in the early stages of developing a diverse portfolio of companies, targeting disruptive technologies that positively impact the environment and emerging economies. Their current focus is on high-efficiency electric tankless water heaters, manufactured and sold under "trutankless", a division of Bollente, including a line of economy tankless water heaters sold under the Vero name. Units are available for both residential and commercial application.

The primary Bollente advantage is their use of advanced technology, superior to previous tankless systems, together with a growing U.S. and global market. Traditional water heaters are one of the costliest appliances to operate. The two primary energy sources used in U.S. homes are electric and natural gas, with less than half of U.S. homes having natural gas available. In addition, there are no significant electric whole home tankless manufacturers.

The U.S. Department of Energy now requires tanks of 55 gallons or more to have efficiency levels requiring expensive heat pumps to achieve. Bollente's trutankless electric tankless water heater employs specialized sensors for constant water temperature, solid state electronics, and proprietary software, resulting in one of the most efficient heat exchangers ever produced. The technology includes smart grid and home automation capabilities, remote control and monitoring, and even smartphone alerts. It also allows adjustable custom power management settings, so that users can further enhance energy usage and performance. It is now estimated that tankless heaters used in every home would save over $8 billion annually in the U.S. alone.

By maintaining 99 percent efficiency, Bollente's trutankless heaters use less energy than tank heaters, while providing the convenience of always-hot water. The system only uses power when there is demand, producing water to exact temperature, within one degree, even with sudden changes to input. Wireless apps allow for remote settings, notifications, and monitoring, and models are compatible with existing home automation and energy management systems. The technology also reduces size, for easy location, and the system's self-flushing design provides up to 20+ years of maintenance free operation, significantly reducing upkeep and replacement costs. This becomes an additional environmental benefit since roughly 8 million used water heaters are dumped in landfills every year.

Bollente has also announced the formation of Bollente International, Inc., a wholly-owned subsidiary, for the international production and sale of trutankless systems. Taking advantage of growing interest in their technology, Bollente International is working with an international manufacturing firm for the production and distribution of trutankless systems throughout Europe, Asia, Australia and New Zealand, with the first step being the testing and certification necessary to meet the various international standards.

Bollente has made electric tankless water heating compelling to a major consumer market, both in and outside the U.S., offering economic as well as operational efficiency and convenience, attractive to builders as well as to end consumers. Disclaimer

Bollente Companies, Inc. Blog

Bollente Companies, Inc. News:

Bollente Companies, Inc. (BOLC) is “One to Watch”

Second Generation of Trutankless® Smart Water Heaters to Be Unveiled At International Builders Show

Bollente Companies, Inc. granted significant patent for its award-winning trutankless® smart water heaters

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX). Today, ChineseInvestors.com closed trading at $1.31, off by 2.96%, on 51,729 volume with 73 trades. The stock’s average daily volume over the past 60 days is 205,701 and its 52-week low/high is $0.12/$2.75.

ChineseInvestors.com today announces its investment in Breakwater MB, LLC, a cannabis-focused investment and consulting company. Building on the success that CIIX enjoyed through its investment in early-stage firm Medicine Man Technologies, the Company is pleased to announce another strategic investment in the cannabis industry. 

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com Blog

ChineseInvestors.com News:

ChineseInvestors.com Announces Investment in Breakwater MB, LLC a Cannabis-Focused Investment and Consulting Company

Alan Klitenic, Director of Investor Relations for ChineseInvestors.com, Discusses Recent CIIX News and Industry Trends in a New Audio Interview with SmallCapVoice.com

ChineseInvestors.com Launches XiBiDi Biotechnology to Reach China's 1.4 Billion Consumer Base

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.053975, off by 3.62%, on 2,947,685 volume with 142 trades. The stock’s average daily volume over the past 60 days is 10,031,482, and its 52-week low/high is $0.0055/$0.142.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring SinglePoint, Inc. (OTC: SING), an NNW client focused on strengthening its position in the marijuana industry through the acquisition of, or investment in, small to mid-sized cannabis companies. The publication is entitled "Marijuana Legalization Could Encourage Widespread Economic Benefits." It describes how, with the help of cannabis-focused innovators, a legalized marijuana industry could create jobs and increase tax revenue. To view the full publication visit: https://www.networknewswire.com/marijuana-legalization-encourage-widespread-economic-benefits/

Singlepoint, Inc. (SING) provides mobile technology and marketing solutions that enable companies, nonprofits and religious organizations to conduct business transactions, accept donations, and engage in targeted communication via mobile devices. Through diversification of its own model, the company is also leveraging its core technology to expand into the mobile auctions and daily fantasy sports markets.

SING currently has two fundraising solutions. Text2Bid is an interactive way to increase auction revenues. The technology makes it easy for people to bid in auctions from any text or web-enabled phone. Donate by Text allows nonprofits to securely collect one-time or recurring donations via text. This capability creates a personal experience for the donors, and enables ongoing communication between the donor and nonprofit or event sponsor.

SING's payment solutions include point-of-sale (POS) terminals, loyalty programs, payment processing, phone services and financing. Pay by Text™ enables a business to accept payment transactions and, in essence, turns the user's mobile phone into a point-of-sale device. Operating on the same platform as mobile marketing, Pay by Text is designed to increase revenues, raise the average per-transaction amount, and create a fast, easy and hassle-free method of payment.

As part of its diversification and expansion strategy, SING recently acquired an interest in DraftFury (www.draftfury.com), a company that offers skill-based NBA, NFL and MLB daily fantasy sports (DFS) contests. DraftFury is known for its innovative offerings and originality, and is the first cash-flow-positive DFS enterprise. This transaction places SING in a multi-billion dollar industry expected to generate entry fees of $14.4 billion in 2020. Under the guidance of a leadership team well-versed in technology, engineering, marketing and raising capital, SING anticipates a strong foothold in its chosen markets. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

NetworkNewsWire Announces Publication that Highlights Marijuana Stocks and Reviews the Economic Benefits Legalization

SinglePoint's Enterprise Strategy Diversifies the Company's Presence in the Cannabis Industry -- CFN Media

NetworkNewsBreaks – Singlepoint, Inc. (SING) CEO Discusses Convectium Acquisition in Interview on MoneyTV

Dominovas Energy Corp. (DNRG)

The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.0007, up 16.67%, on 12,441,675 volume with 24 trades. The stock’s average daily volume over the past 60 days is 15,458,273 and its 52-week low/high is $0.0005/$0.028.

Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.

At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.

In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.

Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer

Dominovas Energy Corp. Blog

Dominovas Energy Corp. News:

Dominovas Energy Obtains Partner to Facilitate Financing, Development and Production for RUBICON(TM) Fuel Cell Systems

Dominovas Energy Continues Discussions with Madagascar for Energy Projects

Dominovas Energy Secures Gas Supply for South Africa

InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.327, up 2.19%, on 544,375 volume with 231 trades. The stock’s average daily volume over the past 60 days is 846,760, and its 52-week low/high is $0.05/$0.4261.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Pharmaceuticals' Unique Approach Featured in Forbes -- CFN Media

InMed's Exceptional Management Team Executes Ambitious Plan -- CFN Media

NetworkNewsWire Announces Publication of Discussion on the R&D of Cannabinoids for Medical Use


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(CDII) +263.95%


Profitable Trader Authority
(GETH) +100.00%


(XBIO) +44.30%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251